- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Screening
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
PrEP for HIV Prevention: A Guideline Update Topline
The CDC update recommends that clinicians advise all sexually active patients about PrEP and includes a new section on prescribing injectable bimonthly cabotegravir.
The Centers for Disease Control and Prevention (CDC) released its Preexposure Prophylaxis for the Prevention of HIV Infection in the United States—2021 Update—A Clinical Practice Guideline in December 2021.
The updates reflect the most recent science and are intended to support clinicians in prescribing all FDA-approved PrEP medications and to increase PrEP use among all those who could benefit.
The most noteworthy new recommendation which applies to all health care providers is to inform all sexually active adults/adolescents about PrEP, an effort to broaden awareness of the treatment option. And, in addition to taking a brief sexual history to identify those with inidications for PrEP, that PrEP be prescribed for anyone who requests it, even if they do not disclose specific risk behaviors. A topline of the guideline updates follows in this short slide show.
Reference: Centers for Disease Control and Prevention. Preexposure Prophylaxis for the Prevention of HIV Infection in the United States – 2021 Update Clinical Practice Guideline. Atlanta, GA: Centers for Disease Control and Prevention, US Public Health Service; 2021.
